Paul Kohlhaas bio/acc
@paulkhls • 27,138 subscribers
building the scientific singularity / founder & ceo @bioprotocol @molecule_sci pioneering DeSci @vita_dao/ alum @Consensys @AfrikaBurn @HSGStgallen
Shorts
Videos
Fun fact: Bio Protocol made +$4m in liquidity fees the past weeks 🪻 Most see $BIO as a "DeSci" launchpad and forget we manage all liquidity pools for BioDAOs & optimise for POL + AUM We're lining up integrations with leading DeFi protocols, including a lending market for $BIO
Paul Kohlhaas bio/acc98,472 次观看 • 9 个月前
Onchain scientific agents may be the start of "vibe science" Stats on $AUBRAI since launch: - 980 novel hypotheses generated and hashed on Base by public contributors - $180k in fees generated for experiments in 8 days on +$20m volume - 145k listeners at Aubrey de Grey's X Spaces unveiling Aubrai to the longevity community Next steps: - Launch terminal for academics and vibe scientists to co-create - Refine hypotheses, design experiments, enable minting IP-NFTs from terminal - Launch Aubrai IPTs on Bio Protocol to fund experiments - $AUBRAI will be gamified for access - RMR2 study begins One big question: who does the IP belong to? Token holders. By contributing IP, users receive $AUBRAI or $USDC Repeat, refine, experiment. We have a lot to improve. I appreciate everyone's support, conviction, feedback, criticism. Most of all I thank Bio Protocol team for tirelessly shipping, day and night, all our incredible DAOs and builders and of course Aubrey de Grey and his incredible team. What's next? We're speaking with the world's *top* scientists in their field to launch agentic systems for them, and simultaneously want to enable all the new DeSci builders and DAOs to succeed. As soon as Aubrai is fully autonomous, many ignition sales will follow permissionlessly and open, in parallel. Succeeding with this while keeping quality extremely high is a very subtle balancing act. First slowly, then all at once. Max stake $BIO, stay patient, you'll need the XP. What's the end goal? Make people feel ok, healthy, safe
Paul Kohlhaas bio/acc67,658 次观看 • 9 个月前
Second Bio Protocol ignition agent sale just fired off with BiomeAI 🚀 And our first IPT on BIO with a novel tokenomic design, keep your third eye open eDMT Commons by PsyDAO Our goal is to keep them flowing sustainably day by day until suddenly a wild Dyson sphere appears 🎆
Paul Kohlhaas bio/acc43,301 次观看 • 8 个月前
“People in crypto generally have a long term outlook. The crypto market actually really wants DeSci What we are seeing some of our DAOs do is generate roadmaps or knowledge trees for entire fields. Lets map it all out. And start deciding where we put that funding. And if it works get more funding. The really beautiful thing here is its solving a problem for two sides. We can solve a problem for patients who I think are comically disenfranchised from value creation in biopharma. And then we solve problems for scientists. If we can make scientists just a little bit richer and participate in this then we’ve won” Beautiful bio/acc edit by a community member of a panel at ResearchHub SciCon last month w/ Rohan Dixit Clarice D. Aiello (she,her)
Paul Kohlhaas bio/acc23,214 次观看 • 1 年前
In the East, fishing villages became skyscrapers in a generation. Imagine Asia applying that same scaling mindset to life science and biotech. Traditional Chinese Medicine (TCM) preserves 2,000 years of systematically recorded clinical insight. Modern studies have explored its formulas, but results are scattered, sample sizes small and omics data very rare. Much is entirely overlooked by the West. Not because it lacks potential, but because the compounds aren’t patentable and there’s little incentive to run trials. I’ve taken lion’s mane and cordyceps for years. I find the impact profound. Asia’s cities virtualized almost overnight. If Asian medicine is digitized, it will leap ahead of the West. What if we start by digitising every TCM protocol? Chemical fingerprints, PK/PD data, real-world outcomes, IP tokenised on chain. Picture community-governed Bio Protocol DAOs in Guangzhou, Singapore, Seoul, and Kuala Lumpur Running adaptive, crowdsourced trials. Rewarding replication. Surfacing lead compounds. Honoring holistic context. Open infrastructure beats closed pipelines. We should start mapping TCM’s heuristics to global standards. I’d love to see a DAO focused on this. $BIO is also looking at running trials in the region and manufacturing. Building in DeSci? In APAC and need funding? DM me
Paul Kohlhaas bio/acc11,672 次观看 • 11 个月前
没有更多内容可加载